Clinical trials: Severe Pneumonia
SARS-CoV Infection, Covid19
Can the Electronic Nose Smell COVID-19 Antibodies?
Corona Virus Disease (COVID-19), spread worldwide and has become an emergency of major international concern. In March 2020, the WHO declared the COVID-19 outbreak a global pandemic.
- Trial name
- NCT04475575
- Testing
- Aeonose
- Where
- Netherlands
- Volunteers
- 222 people
- Sponsor
- Maastricht University Medical Center
Severe Acute Respiratory Syndrome Coronavirus 2
Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients
This trial is designed to determine if the inflammation modulating effect of vagus nerve stimulation can improve pulmonary function and limit progression to ARDS in hospitalized COVID-19 hospitalized patients.
- Trial name
- NCT04379037
- Testing
- Transcutaneous Auricular Vagus Nerve Stimulation
- Where
- Argentina
- Volunteers
- 50 people
- Sponsor
- Nemechek Technologies
COVID-19
PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
This study looks at the safety and effectiveness of PF-07304814 in treating COVID-19 in people who have been hospitalized with the infection.
- Trial name
- NCT05780541
- Testing
- PF-07304814, Remdesivir
- Where
- 40 sites in United States, Denmark
- Volunteers
- 58 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19 Infection, Encephalitis
Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection
Emergence of Covid-19 virus is associated with high frequency of extremely severe clinical pictures, with minor signs of CNS impairment (e.g. anosmia, headache).
- Trial name
- MARNEVO-Covid (NCT04361344)
- Testing
- blood samples
- Where
- France
- Volunteers
- 2 people
- Sponsor
- Centre Hospitalier de PAU
COVID-19
A Study on Paxlovid Once in the Market, to Observe Its Safety and Effectiveness in Patients Who Have a High Chance of Getting Severe COVID-19
The purpose of this study is to look at the safety and effectiveness of PAXLOVID in the real world and not in clinical studies. The study observes patients who have a high chance of getting severe COVID-19 in Korea.
- Trial name
- NCT05890612
- Where
- South Korea
- Volunteers
- 3,000 people
- Sponsor
- Pfizer
SARS-CoV-2 Infection
A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19
The purpose of this post marketing observational study is to learn about the safety and effects of the commercial medicine (called PAXLOVID) for the treatment of COVID-19.
- Trial name
- NCT05263908
- Testing
- nirmatrelvir / ritonavir
- Where
- Japan
- Volunteers
- 3,346 people
- Sponsor
- Pfizer
Covid19
Defibrotide for the Treatment of Severe COVID-19
The goal of this study is to evaluate the safety and feasibility of defibrotide in COVID-19 pneumonia.
- Trial name
- NCT04652115
- Testing
- Defibrotide
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Severe COVID-19
Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients
Efficacy and Safety of DWJ1248 with Remdesivir in Severe COVID-19 Patients
- Trial name
- NCT04713176
- Testing
- DWJ1248 with Remdesivir
- Where
- South Korea
- Volunteers
- 240 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Coronavirus, Coronavirus Infection
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate…
- Conditions
- Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2, Pneumonia
- Trial name
- CYNKCOVID (NCT04365101)
- Testing
- CYNK-001
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Celularity Incorporated
Community-acquired Pneumonia, Covid19
Study of a Possible Respiratory Degradation Prognosis Caused by Biomarkers in Severe Forms of COVID-19 Pneumonia
Respiratory infection with the SARS-CoV2 virus is associated with a major risk of viral pneumonia that can lead to respiratory distress requiring resuscitation.
- Trial name
- LPSARS2 (NCT04505605)
- Testing
- Blood samples
- Where
- 2 sites in France
- Volunteers
- 20 people
- Sponsor
- Fondation Hôpital Saint-Joseph
COVID-19, Health Behavior
How Future Surgery Will Benefit From Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Related Measures Perspective From Italian Young Surgeon Society (SPIGC)
The coronavirus 2019 pandemic (COVID-19) strongly affected clinical care worldwide. Due to a shortage of hospitals and beds in intensive care units (ICU), in Italy during outbreaks, surgical resources were temporarily and…
- Trial name
- NCT05323851
- Testing
- COVID-surg-SPIGC questionnaire
- Where
- 3 sites in Italy
- Volunteers
- 581 people, healthy volunteers welcome
- Sponsor
- University of Rome Tor Vergata
Covid19
Anti COVID 19 Hyperimmune Intravenous Immunoglobulin (C-IVIG) Therapy for Severe COVID-19 Patients
Severe ill Patients will be enrolled in the study (n=310) after duly filled consent forms. Recipients will be divided into 2 group, each group contain 155 patients to compare Safety and efficacy of patients in Clinical Trial…
- Trial name
- NCT04891172
- Testing
- Anti COVID 19 Intravenous Immunoglobulin (C-IVIG)
- Where
- Pakistan
- Volunteers
- 310 people
- Sponsor
- Dow University of Health Sciences
COVID19
Could Docosahexaenoic Acid (DHA), Contained in Breast Milk and Artificial Baby Milks, Protect Infants and Children From COVID-19 and Make Them Less Prone to COVID-19-related Severe Illness Than Adults?
Could Docosahexaenoic Acid (DHA) Protect Infants and Children From COVID-19 and Make Them Less Susceptible to COVID-19-related Severe Illness Than Adults? The study is configured as a retrospective and prospective observational…
- Trial name
- NCT05075031
- Volunteers
- 1,500 people
- Sponsor
- Kafrelsheikh University
COVID-19
Coronavirus Disease 2019 (COVID-19) Antibody Plasma Research Study in Hospitalized Patients
The purpose of this research study is to find out if CCP is safe and to determine the safest and most effective level of anti-viral antibody when given to people admitted to the hospital with confirmed COVID-19 infection.
- Trial name
- UNC CCP RCT (NCT04524507)
- Testing
- High-titer Convalescent COVID-19 Plasma (CCP1), Standard-titer Convalescent COVID-19 plasma (CCP2)
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- University of North Carolina, Chapel Hill
Covid19
Observational, Retrospective Study to Evaluate Coagulation Changes and the Influence of Antithrombin III Treatment in Patients With Severe COVID-19 Infection
Multicentre, multinational, non-interventional, observational, retrospective, patient record study to evaluate changes in coagulation parameters in patients with severe COVID-19 infection receiving/not treatment with antithrombin…
- Trial name
- NCT04651400
- Testing
- Antithrombin III
- Where
- 6 sites in Austria, France and 2 more
- Volunteers
- 300 people
- Sponsor
- Octapharma
Respiratory Insufficiency, Pneumonia
High Flow Nasal Cannulae vs Venturi Mask in Respiratory Failure Due to Pneumonia
The primary objective of this study is to compare the efficacy of treatment with HFNC (group A) compared to administration of oxygen therapy by Venturi mask (group B, standard therapy) in terms of reaching of endotracheal…
- Trial name
- HiFlOViP (NCT03515031)
- Testing
- High Flow Nasal Cannula Oxygenation, Venturi Mask Oxygenation
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Papa Giovanni XXIII Hospital
Covid19, Diabetes Mellitus
Incidence and Predictors of Acute and Chronic Complications in Patients With Diabetes and Severe COVID-19
All surviving patients of the Michigan Medicine COVID-19 Cohort (M2C2, PI: Hayek) that were admitted to the University of Michigan for severe COVID-19 disease are eligible for this study.
- Trial name
- NCT05200819
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Michigan
Mycobacterium Avium-Intracellulare Infection
A Randomized, Double-Blinded, Placebo-Controlled, Phase II Inhaled Interferon Gamma-1b and Antimycobacterials to Treat Pulmonary Mycobacterium Avium Complex Infections
This study will test the safety and effectiveness of inhaled interferon gamma-1b and oral antibiotics for treating mycobacterium avium complex (MAC) infection of the lungs.
- Trial name
- NCT00021567
- Testing
- Interferon Gamma for Aerosol
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Covid19 Pneumonia
The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation
Title: The use of Tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation.
- Trial name
- NCT04377750
- Testing
- Tocilizumab
- Where
- 4 sites in Israel
- Volunteers
- 500 people
- Sponsor
- Hadassah Medical Organization
COVID-19
Prevalence of Severe Bleeding in COVID-19 Patients Treated With Higher Than Recommended Thromboprophylaxis Doses
The main objectives are: To establish the prevalence of major bleeding in patients treated with higher than recommended thromboprophylaxis doses. To identify variables associated to higher risk of bleeding.
- Trial name
- BLEEDING (NCT04380779)
- Where
- Spain
- Volunteers
- 2,430 people
- Sponsor
- Manuel Monreal
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.